Disagree here. Yes, generics will benefit one way or another from this if V is proven beneficial to co19 patients; but it also increase EU valuation which is almost the only piece we have.
Beside this is a great opportunity if amrn want to utilize media to influence the appeal court. So I only hope things are happening behind scene as Zu suggested and we wil know soon.
rtc1110 - I concede your point, but damn the torpedoes... if V can help reduce mortality (and I bet it does because it hits all factors (oxidation, inflammation , endothelial dysfunction, anti thrombosis) AMRN valuation gets adjusted up big time. Prophylactic use will skyrocket from "halo" effect. Its a problem I'm ok having. - also think what it will do for a euro partner deal?
No elephant will appear until FDA approves an ANDA filed by some generic house for a composition that =s Vascepa in safety and efficacy.
I currently am unaware of any FDA- approved medication that reduces health care costs as much as Vascepa at $36 per year. Low dose aspirin might come close; medical advice remains ambiguous re discontinuing aspirin use if taking Vascepa
News 
Market Data 
Discover 
